Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Serial plasma osteopontin levels have prognostic value in metastatic breast cancerVivien H C Bramwell, Gordon S Doig, Alan B Tuck, et al.
Breast Cancer Research and Treatment|April 26, 2008
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancerVivien H C Bramwell, Gordon S Doig, Alan B Tuck, et al.
Molecular Cancer Research : MCR|October 1, 2003
Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontinKara A Furger, Alison L Allan, Sylvia M Wilson, et al.
BMC Cancer|August 25, 2016
The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancerMilica Krstic, Connor D Macmillan, Hon S Leong, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast CancerMuriel Brackstone, David Palma, Alan B Tuck, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 20, 2011
Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasisBrigitte Goulet, Wendy Kennette, Amber Ablack, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 14, 2007
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivoMarianne M Stanford, Mae Shaban, John W Barrett, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 8, 2014
Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblastsDaichi Ota, Masashi Kanayama, Yutaka Matsui, et al.
Plos One|May 1, 2012
Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LNMousumi Majumder, Elena Tutunea-Fatan, Xiping Xin, et al.
Clinical Chemistry|March 28, 2009
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAsPieter H Anborgh, Sylvia M Wilson, Alan B Tuck, et al.
Pageof 13